WHO European Region · country profile

HIV, PrEP and sexual health access in Spain

Name: HIV medicine, PrEP and sexual health access in Spain
Creator: SHAPE

Spain: 74% of verified HIV medicine records are reimbursed; PrEP is available and reimbursed; sexuality education is classified as progressive. Compare medicines, prevention, reproductive rights and migrant healthcare access, with sources and the date each record was last checked.

Last checked 02/11/2026 · Sources cited on every record

Colour shows the share of verified HIV medicines that are reimbursed.

HIV medicines74% reimbursed23 of 31 verified records PrEPReimbursed34,247 PrEP recipients (2024; UNAIDS GAM)DoxyPEPAvailable, not reimbursedNational access and guidance Sexuality educationProgressivePolicy framework Family planning & abortionProgressiveAbortion law and contraception Migrant healthcare accessSuccessEntitlement and practice

11 HIV medicine records for Spain are still under review. They have not yet been checked against a national source and must not be read as confirmed access or non-access.

Are HIV medicines reimbursed in Spain?

Of 31 verified HIV medicine records for Spain, 23 are available and reimbursed (74%), 2 are available but not reimbursed and 6 are not available. 11 further records are still under review.

Reimbursed 23

Apretude, Biktarvy, Celsentri, Delstrigo, Descovy, Dovato, Edurant, Generic TDF/FTC (Emtricitabine/Tenofovir DF), Genvoya, Intelence, Isentress, Juluca, Kaletra, Odefsey and 9 more

Available, not reimbursed 2

Rukobia, Sunlenca

Not available 6

Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris, Emtricitabine / Tenofovir alafenamide Viatris, Evotaz, Generic TLD (Tenofovir/Lamivudine/Dolutegravir), Generic TLE (Tenofovir/Lamivudine/Efavirenz), Reyataz

See every medicine with its source ↓

Is PrEP available and reimbursed in Spain?

Yes. In SHAPE's review, PrEP is available and reimbursed in Spain.

PrEP recipients: 34,247 PrEP recipients (2024; UNAIDS GAM)

PrEP has been included in Spain's National Health System benefit package since 2019 and is supplied through authorized public services for eligible people. [Source: https://www.sanidad.gob.es/gabinete/notasPrensa.do?id=5832] UNAIDS GAM 2025 reports 34,247 people receiving PrEP in 2024. This is a service-use count, not a population coverage percentage, and it does not determine reimbursement. [Source: https://aidsinfo.unaids.org/dataset]

Is DoxyPEP available in Spain?

DoxyPEP can be accessed in Spain, but SHAPE's review did not find it reimbursed.

Spanish expert guidance treats DoxyPEP as off-label and individualized for men who have sex with men and transgender women with repeated STIs, not for systematic use; national reimbursement was not confirmed. [Source: https://www.sanidad.gob.es/areas/DCVIHT/ITS/docs/seimc-rc-2024-GEITS-GEMARA-GeSIDA-Posicionamiento-DoxiPEP.pdf]

What is the policy on sexuality education in Spain?

SHAPE classifies the sexuality education framework in Spain as progressive. This describes the national policy framework, not how every school delivers it.

National framework: National education law requires affective-sexual education, equality and violence prevention, while implementation and curriculum detail vary among autonomous communities.
Interpretation: The status summarizes the verified policy framework; it does not guarantee uniform classroom delivery.

[Sources: https://www.unesco.org/gem-report/en/peer ; https://www.who.int/news-room/fact-sheets/detail/comprehensive-sexuality-education ; https://www.bzga-whocc.de/fileadmin/user_upload/Dokumente/BZgA_IPPFEN_ComprehensiveStudyReport_Online.pdf]

What are the rules on abortion and contraception in Spain?

SHAPE classifies family planning and abortion rights in Spain as progressive, combining abortion law and contraception policy.

Abortion: Abortion is available on request through 14 weeks. Since the 2023 reform, 16- and 17-year-olds do not require parental consent and the mandatory reflection period was removed.
Contraception: EPF's 2026 contraception-policy score is 68.8%; the atlas records partial national coverage.
Interpretation: The status combines legal rules and national policy access; regional availability and individual eligibility may differ.

[Sources: https://abortion-policies.srhr.org/countries/ ; https://www.epfweb.org/sites/default/files/2026-02/CCInfoEU_A3_EN_2026_FEB22-HiRes.pdf]

Can migrants access healthcare in Spain?

SHAPE's editorial comparison places migrant healthcare access in Spain in the most accessible category (Success). Entitlement: 2026 national procedure for people without legal residence.

Provider type: National/regional health system / primary care / NGO · International migrants (2024): 8,870,527

Access rule: A March 2026 national procedure standardises publicly funded care for foreign nationals without legal residence, using a declaration and provisional coverage while eligibility is decided.
Main barriers: Proof, local implementation, registration, language and fear can still affect uptake despite the national route.
Migration measure: UN DESA estimates 8,870,527 international migrants at mid-year 2024. This is a point-in-time stock, not the number of people who arrived during 2024. The estimate is based on the foreign-born population. Refugee, asylum-seeker or refugee-like population data are incorporated where indicated by UN DESA.
Origin definition: The origin shares below use country or area of birth for foreign-born estimates and country of citizenship for foreign-citizen estimates. They do not establish a person's nationality, ethnicity, language, reason for migration, legal status, recent-arrival status or undocumented status.
Measurement basis: Foreign-born population + refugee/asylum adjustments (UN DESA code B R)
Evidence note: ECDC indicators use 2024 reports: the foreign-born share is calculated only among diagnoses with known origin; late diagnosis is the country-level share with CD4 <350 cells/µL and is not migrant-specific. Data Unavailable means no sufficiently interpretable value was published; a blank is not zero. The status is an editorial comparison of legal entitlement and practical access and does not apply equally to every migrant group.

Main origins: Morocco (12.3%), Colombia (8.9%), Venezuela (Bolivarian Republic of) (6.8%)

Selected HIV indicators: Foreign-born HIV Diagnoses (known origin, 2024): 55.1%; Late HIV Diagnosis (CD4 <350, 2024): 51.1%

How Spain compares

Spain ranks #35 of 53 countries with enough verified HIV medicine records, by share of records that are reimbursed (74%; median 82%).

0%Marker: median of all countries100%

Neighbouring and nearby countries

Portugal92%France95%Andorra83%Monaco83%

All HIV medicines in Spain

Medicine	Active ingredient	Class	Status	Evidence and source	Checked
Apretude ViiV Healthcare	Cabotegravir (PrEP)	INSTI (Long-Acting PrEP)	Reimbursed	Authorised and marketed in Spain. Public financing was approved with restrictions: HIV-negative people weighing at least 35 kg who meet the criteria for oral tenofovir/emtricitabine PrEP and have an additional reason, such as hypersensitivity, kidney or bone problems, swallowing difficulty, adherence problems or chemsex. The effective date of financing is not stated in the sources. [Sources: https://www.sanidad.gob.es/areas/farmacia/precios/comisionInteministerial/informesPublicos/docs/InformePublicoApretude.pdf (published 29 April 2026) ; https://www.sanidad.gob.es/gabinete/notasPrensa.do?id=6860 (26 February 2026)]	02/11/2026
Biktarvy Gilead Sciences	Bictegravir / Emtricitabine / TAF	INSTI + NRTI/NtRTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Celsentri ViiV Healthcare	Maraviroc	Entry Inhibitor	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Delstrigo Merck	Doravirine / Lamivudine / Tenofovir DF	NNRTI + NRTI/NtRTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Descovy Gilead Sciences	Emtricitabine / TAF	NRTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Dovato ViiV Healthcare	Dolutegravir / Lamivudine	INSTI + NRTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Edurant Janssen	Rilpivirine	NNRTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Generic TDF/FTC (Emtricitabine/Tenofovir DF) Multiple (Generics)	Emtricitabine / Tenofovir DF	NRTI	Reimbursed	Generic combinations are widely accessible and reimbursed under standard national health policies. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Genvoya Gilead Sciences	Elvitegravir / Cobicistat / Emtricitabine / TAF	INSTI + NRTI/NtRTI + pharmacokinetic enhancer	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Intelence Janssen	Etravirine	NNRTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Isentress Merck	Raltegravir	INSTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Juluca ViiV Healthcare	Dolutegravir / Rilpivirine	INSTI + NNRTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Kaletra AbbVie	Lopinavir / Ritonavir	PI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Odefsey Gilead Sciences	Rilpivirine / Emtricitabine / TAF	NNRTI + NRTI/NtRTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Pifeltro Merck	Doravirine	NNRTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Prezista Janssen	Darunavir	PI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Rekambys Janssen	Rilpivirine	Long-Acting NNRTI	Reimbursed	Long-acting injectable rilpivirine used with cabotegravir for maintenance treatment in eligible virologically suppressed patients. The existing Spain record for the complete Vocabria / Rekambys regimen is classified as 'Available and Reimbursed', so this required rilpivirine component uses the same access and reimbursement status. EU regulatory update (as of 5 Oct 2026): on 31 January 2025 the European Commission extended the authorisation of Vocabria plus Rekambys long-acting injections to virologically suppressed adolescents aged 12 years and older weighing at least 35 kg (adults authorised since December 2020). National reimbursement for adolescents not verified. [Sources: https://www.ema.europa.eu/en/medicines/human/EPAR/rekambys; https://www.pharmiweb.com/press-release/2025-01-31/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents-1; https://i-base.info/htb/50121]	14/09/2026
Symtuza Janssen	Darunavir / Cobicistat / Emtricitabine / TAF	PI + NRTI/NtRTI + pharmacokinetic enhancer	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. EU regulatory update (as of 5 Oct 2026): on 25 June 2026 the CHMP adopted a positive opinion extending the indication, with a new 675/150/200/10 mg tablet strength, to adults and paediatric patients aged 6 years and older weighing at least 25 kg (previously adolescents aged 12 years and older weighing at least 40 kg). European Commission decision not confirmed during this review; national availability and reimbursement of the new strength not verified. [Sources: Local Ministry of Health / ECDC reports; https://www.ema.europa.eu/en/medicines/human/variation/symtuza]	14/09/2026
Tivicay ViiV Healthcare	Dolutegravir	INSTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Triumeq ViiV Healthcare	Dolutegravir / Abacavir / Lamivudine	INSTI + NRTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Truvada Gilead Sciences	Emtricitabine / Tenofovir DF	NRTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Vocabria ViiV Healthcare	Cabotegravir	INSTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. EU regulatory update (as of 5 Oct 2026): on 31 January 2025 the European Commission extended the authorisation of Vocabria plus Rekambys long-acting injections to virologically suppressed adolescents aged 12 years and older weighing at least 35 kg (adults authorised since December 2020). National reimbursement for adolescents not verified. [Sources: Local Ministry of Health / ECDC reports; https://www.pharmiweb.com/press-release/2025-01-31/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents-1; https://i-base.info/htb/50121]	14/09/2026
Vocabria / Rekambys ViiV Healthcare / Janssen	Cabotegravir / Rilpivirine	Long-Acting ART	Reimbursed	EMA approved. Fully or partially reimbursed under the national health system for virologically suppressed patients. EU regulatory update (as of 5 Oct 2026): on 31 January 2025 the European Commission extended the authorisation of Vocabria plus Rekambys long-acting injections to virologically suppressed adolescents aged 12 years and older weighing at least 35 kg (adults authorised since December 2020). National reimbursement for adolescents not verified. [Sources: Local Ministry of Health / ECDC reports; https://www.pharmiweb.com/press-release/2025-01-31/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents-1; https://i-base.info/htb/50121]	14/09/2026
Rukobia ViiV Healthcare	Fostemsavir	Attachment Inhibitor	Available, not reimbursed	Approved by EMA, but may require special funding requests or is restricted to highly treatment-experienced patients. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Sunlenca Gilead Sciences	Lenacapavir	Capsid Inhibitor	Available, not reimbursed	Approved by EMA, but may require special funding requests or is restricted to highly treatment-experienced patients. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris Viatris Limited	Emtricitabine / Rilpivirine / Tenofovir alafenamide	NNRTI + NRTI/NtRTI	Not available	Authorised in Spain in February 2026 but not yet marketed according to the AEMPS medicines register (CIMA), checked 2 November 2026. [Source: https://cima.aemps.es/cima/rest/medicamentos?nombre=tenofovir%20alafenamida%20viatris]	02/11/2026
Emtricitabine / Tenofovir alafenamide Viatris Viatris Limited	Emtricitabine / Tenofovir alafenamide	NRTI/NtRTI	Not available	Authorised in Spain in February 2026 but not yet marketed according to the AEMPS medicines register (CIMA), checked 2 November 2026. [Source: https://cima.aemps.es/cima/rest/medicamentos?nombre=tenofovir%20alafenamida%20viatris]	02/11/2026
Evotaz Bristol Myers Squibb	Atazanavir / Cobicistat	PI + pharmacokinetic enhancer	Not available	Authorised in Spain but not marketed according to the AEMPS medicines register (CIMA), checked 2 November 2026. [Source: https://cima.aemps.es/cima/rest/medicamentos?nombre=evotaz]	02/11/2026
Generic TLD (Tenofovir/Lamivudine/Dolutegravir) Multiple (Generics)	Tenofovir DF / Lamivudine / Dolutegravir	INSTI + NRTI/NtRTI	Not available	Generic combinations are typically not procured as branded single-tablet regimens are widely available. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Generic TLE (Tenofovir/Lamivudine/Efavirenz) Multiple (Generics)	Tenofovir DF / Lamivudine / Efavirenz	NNRTI + NRTI/NtRTI	Not available	Generic combinations are typically not procured as branded single-tablet regimens are widely available. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Reyataz Bristol Myers Squibb	Atazanavir	PI	Not available	Authorised in Spain but not marketed according to the AEMPS medicines register (CIMA), checked 2 November 2026. [Source: https://cima.aemps.es/cima/rest/medicamentos?nombre=reyataz]	02/11/2026
Emtriva Gilead Sciences	Emtricitabine	NRTI	Under review	Emtricitabine is a nucleoside reverse transcriptase inhibitor used with other antiretroviral medicines for HIV-1 treatment. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/emtriva]	14/09/2026
Epivir ViiV Healthcare	Lamivudine	NRTI	Under review	Lamivudine is a nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/epivir]	14/09/2026
Eviplera Gilead Sciences	Rilpivirine / Emtricitabine / Tenofovir DF	NNRTI + NRTI/NtRTI	Under review	A once-daily fixed-dose HIV-1 regimen containing rilpivirine, emtricitabine and tenofovir disoproxil; resistance history and viral-load restrictions apply. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/eviplera]	14/09/2026
Kivexa ViiV Healthcare	Abacavir / Lamivudine	NRTI	Under review	A fixed-dose NRTI backbone containing abacavir and lamivudine; HLA-B*5701 screening is required before abacavir treatment. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/kivexa]	14/09/2026
Norvir AbbVie	Ritonavir	PI + pharmacokinetic enhancer	Under review	Ritonavir is a protease inhibitor used mainly at low dose as a pharmacokinetic enhancer for other protease inhibitors. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. EU regulatory update (as of 5 Oct 2026): on 18 September 2025 the CHMP adopted a positive opinion recommending changes to the existing indication and contraindications of Norvir, including guidance that when ritonavir is used as a pharmacokinetic enhancer the SmPC of the co-administered protease inhibitor should be consulted for contraindications. European Commission decision not confirmed during this review. [Sources: https://www.ema.europa.eu/en/medicines/human/EPAR/norvir; https://www.ema.europa.eu/en/medicines/human/variation/norvir]	14/09/2026
Retrovir ViiV Healthcare	Zidovudine	NRTI	Under review	Zidovudine is a nucleoside reverse transcriptase inhibitor used with other antiretroviral medicines; it is now generally a specialised or alternative treatment option. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/retrovir]	14/09/2026
Rezolsta Janssen	Darunavir / Cobicistat	PI + pharmacokinetic enhancer	Under review	A fixed-dose combination of darunavir and cobicistat used with other antiretrovirals. EMA's CHMP issued a positive opinion on 25 June 2026 for a dispersible formulation and paediatric use from age 3 years and 15 kg. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta]	14/09/2026
Stribild Gilead Sciences	Elvitegravir / Cobicistat / Emtricitabine / Tenofovir DF	INSTI + NRTI/NtRTI + pharmacokinetic enhancer	Under review	A once-daily fixed-dose HIV-1 regimen containing an integrase inhibitor, pharmacokinetic enhancer and two reverse transcriptase inhibitors. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/stribild]	14/09/2026
Viread Gilead Sciences	Tenofovir DF	NtRTI	Under review	Tenofovir disoproxil is a nucleotide reverse transcriptase inhibitor used with other antiretrovirals for HIV-1 treatment; renal and bone monitoring may be relevant. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/viread]	14/09/2026
Yeytuo Gilead Sciences	Lenacapavir (PrEP)	Capsid Inhibitor (Long-Acting PrEP)	Under review	Twice-yearly injectable lenacapavir for pre-exposure prophylaxis; a separate marketing authorisation from Sunlenca, which covers treatment. The European Commission granted an EU/EEA-wide marketing authorisation on 26 August 2025 following accelerated EMA assessment. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/yeytuo]	14/09/2026
Ziagen ViiV Healthcare	Abacavir	NRTI	Under review	Abacavir is a nucleoside reverse transcriptase inhibitor used in combination therapy; HLA-B*5701 screening is required before treatment. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/ziagen]	14/09/2026

Sources

The evidence notes above quote these sources. Each record keeps its own source and last-checked date.

sanidad.gob.es https://www.sanidad.gob.es/gabinete/notasPrensa.do?id=5832
aidsinfo.unaids.org https://aidsinfo.unaids.org/dataset
sanidad.gob.es https://www.sanidad.gob.es/areas/DCVIHT/ITS/docs/seimc-rc-2024-GEITS…
unesco.org https://www.unesco.org/gem-report/en/peer
who.int https://www.who.int/news-room/fact-sheets/detail/comprehensive-sexua…
bzga-whocc.de https://www.bzga-whocc.de/fileadmin/user_upload/Dokumente/BZgA_IPPFE…
abortion-policies.srhr.org https://abortion-policies.srhr.org/countries/
epfweb.org https://www.epfweb.org/sites/default/files/2026-02/CCInfoEU_A3_EN_20…
who.int https://www.who.int/europe/health-topics/refugee-and-migrant-health
ecdc.europa.eu https://www.ecdc.europa.eu/en/publications-data/hivaids-surveillance…
home-affairs.ec.europa.eu https://home-affairs.ec.europa.eu/policies/migration-and-asylum/asyl…
health.ec.europa.eu https://health.ec.europa.eu/social-determinants/migrants-health_en
sanidad.gob.es https://www.sanidad.gob.es/gabinete/notasPrensa.do?id=6866
sanidad.gob.es https://www.sanidad.gob.es/areas/farmacia/precios/comisionInteminist…
sanidad.gob.es https://www.sanidad.gob.es/gabinete/notasPrensa.do?id=6860
cima.aemps.es https://cima.aemps.es/cima/rest/medicamentos?nombre=tenofovir%20alaf…
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/emtriva
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/epivir
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/eviplera
cima.aemps.es https://cima.aemps.es/cima/rest/medicamentos?nombre=evotaz
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/kivexa
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/norvir
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/variation/norvir
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/rekambys
pharmiweb.com https://www.pharmiweb.com/press-release/2025-01-31/european-commissi…
i-base.info https://i-base.info/htb/50121
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/retrovir
cima.aemps.es https://cima.aemps.es/cima/rest/medicamentos?nombre=reyataz
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/stribild
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/variation/symtuza
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/viread
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/yeytuo
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/ziagen

Explore more

HIV medicine map PrEP and DoxyPEP map Reproductive autonomy map Health equity dashboard All countries

This page is for public information and policy discussion and is not medical or legal advice. Found an outdated record or a newer official source? Tell us.